PARP inhibitor counteracts Temozolomide Resistance in Glioblastoma Multiforme
Édouard Samarut, Gaston Tabourel, Joséphine Briand, Yuna Landais, Catherine Gratas, Delphine Loussouarn, Gwenola Bougras-Cartron, Pierre‐François Cartron, François M. Vallette, Céline Salaud, Lisa Oliver, Aurélien A. Sérandour
This paper shows that combining temozolomide with the PARP inhibitor olaparib overcomes TMZ resistance in glioblastoma by restoring sensitivity in MMR-deficient and MGMT-expressing cells.
bioRxiv · Dec 13, 2024 · PreprintCancer Biology